JOURNEY MEDICAL CORP
DERMNASDAQTrading Snapshot
- Day Range
- $6.41 – $6.56
- 52-Week Range
- $4.31 – $9.56
- Volume
- $2.01B
- Avg Volume
- $2.10B
- Shares Outstanding
- 27.5M
- Next Earnings
- Nov 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $62M
- Last Q Revenue
- $19M
- P/E Ratio
- -27.2
- P/S Ratio
- 2.5x
- EPS (TTM)
- $-0.22
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +10.6%
Why Investors Own DERM
- ✓High-growth profile — revenue up +47.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 61% gross margin and 14% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
JOURNEY MEDICAL CORP
DERM
StockOtter · stockotter.spaceAbout JOURNEY MEDICAL CORP
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Journey Medical: A Small Pharma With A Large Growth Opportunity
Journey Medical (DERM) is rated Buy, driven by Emrosi's rapid prescription growth and expanding payer coverage. DERM leverages existing infrastructure for Emrosi, achieving high gross margins and operating leverage, push
Journey Medical Corporation to Participate in September 2026 Investor Conferences
SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S. Food and D
ELTP vs. DERM: Which Specialty Pharmaceutical Stock Is the Better Buy?
Elite Pharmaceuticals and Journey Medical follow different growth paths, but which looks more compelling now? Let's dive in.
Journey Medical: Q2 Report Confirms Thesis On Track As Emrosi Launch Gains Traction
Journey Medical demonstrates strong Emrosi prescription growth, rebounding from Q1 lows with Q2 revenues up 23% to $18.5M and positive EBITDA. DERM's Emrosi franchise is gaining traction, with prescribers rising over 40%
Journey Medical Corporation (DERM) Q2 2026 Earnings Call Transcript
Journey Medical Corporation (DERM) Q2 2026 Earnings Call Transcript
Here's What Key Metrics Tell Us About Journey Medical (DERM) Q2 Earnings
The headline numbers for Journey Medical (DERM) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the yea